» Articles » PMID: 17161251

Myocardial Glucose Transport and Utilization in Patients with Type 2 Diabetes Mellitus, Left Ventricular Dysfunction, and Coronary Artery Disease

Overview
Date 2006 Dec 13
PMID 17161251
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This research was designed to assess the effect of type 2 diabetes mellitus (T2DM) on myocardial glucose utilization in patients with heart failure secondary to coronary artery disease.

Background: Patients with T2DM and coronary artery disease have an increased morbidity and mortality compared with patients with coronary artery disease without diabetes that may relate to a reduction in the ability of the myocardium to utilize glucose.

Methods: Myocardial blood flow and glucose utilization were assessed during a hyperinsulinemic clamp by 18F-flurodeoxyglucose and positron emission tomography in 54 patients (19 with T2DM) with multivessel coronary artery disease and heart failure. In a subgroup of 18 patients, myocardial biopsies were obtained during coronary bypass surgery to assess glucose transporter (GLUT4) distribution and protein concentration, and compared with myocardium from transplant donor hearts.

Results: Myocardial blood flow was similar in patients without diabetes and those with T2DM. Myocardial glucose utilization was lower in patients with T2DM (0.34 +/- 0.16 vs. 0.47 +/- 0.24 micromol x min(-1) x g(-1), p = 0.0002) despite comparable plasma insulin concentrations and a higher blood glucose concentration. Extraction of glucose by the myocardium was reduced in patients with T2DM (7.1 +/- 3.1% vs. 13.5 +/- 5.2%, p < 0.01). Myocardial GLUT4 protein was similar in patients with and without T2DM (p = 0.75).

Conclusions: Patients with coronary artery disease and heart failure exhibit myocardial insulin resistance, and this is greater in those with T2DM. This may limit the ability of the myocardium in patients with T2DM to withstand ischemia and may contribute to the increased cardiovascular morbidity and mortality in such patients.

Citing Articles

A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.

Giangregorio F, Mosconi E, Debellis M, Provini S, Esposito C, Garolfi M J Clin Med. 2024; 13(19).

PMID: 39407941 PMC: 11478146. DOI: 10.3390/jcm13195880.


Human cardiac metabolism.

Bornstein M, Tian R, Arany Z Cell Metab. 2024; 36(7):1456-1481.

PMID: 38959861 PMC: 11290709. DOI: 10.1016/j.cmet.2024.06.003.


Association between triglyceride glucose-body mass index and long-term adverse outcomes of heart failure patients with coronary heart disease.

Lyu L, Wang X, Xu J, Liu Z, He Y, Zhu W Cardiovasc Diabetol. 2024; 23(1):162.

PMID: 38724999 PMC: 11080126. DOI: 10.1186/s12933-024-02213-2.


Inhibition of Pyruvate Dehydrogenase in the Heart as an Initiating Event in the Development of Diabetic Cardiomyopathy.

Elnwasany A, Ewida H, Szweda P, Szweda L Antioxidants (Basel). 2023; 12(3).

PMID: 36979003 PMC: 10045649. DOI: 10.3390/antiox12030756.


Glucose dysregulation and subclinical cardiac dysfunction in older adults: The Cardiovascular Health Study.

Garg P, Biggs M, Kizer J, Shah S, Psaty B, Carnethon M Cardiovasc Diabetol. 2022; 21(1):112.

PMID: 35725477 PMC: 9210635. DOI: 10.1186/s12933-022-01547-z.